{"id":3993,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/flecainide-acetate-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"flecainide-acetate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/flecainide-acetate-txt\/","title":{"rendered":"Flecainide acetate.txt"},"content":{"rendered":"

Flecainide acetate <\/h1>\n

CLINICAL USE <\/H3>
\nClass Ic anti-arrhythmic agent:Ventricular arrhythmias and tachycardias

DOSE IN NORMAL RENAL FUNCTION <\/H3>Supraventricular arrhythmias: 100\u2013300 mg daily in 2 divided dosesVentricular arrhythmias: 200\u2013400 mg daily in 2 divided dosesIV bolus: 2 mg\/kg over 10\u201330 minutes (maximum 150 mg), then

IV infusion <\/H4> of 1.5 mg\/kg\/hour for 1 hour, subsequently 0.1\u20130.25 mg\/kg\/hour; maximum 600 mg in 24 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :474.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :32\u201358<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 42<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :8.31<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :12\u201327\/19\u201326

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : See \u2018Other Information\u2019
  • 10 to 20 &nbsp &nbsp : See \u2018Other Information\u2019
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:\u22481% dialysed.1 Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :\u22481% dialysed.1 Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Minimal removal. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: concentration increased by amiodarone \u2013 halve dose of flecainide; increased myocardial depression with other anti-arrhythmics\n
  • Antidepressants: concentration increased by fluoxetine; increased risk of ventricular arrhythmias with tricyclicsAntihistamines: increased risk of ventricular arrhythmias with mizolastineAntihypertensives: increased myocardial depression and bradycardia with beta-blockers; increased myocardial depression and asystole with verapamil\n
  • Antimalarials: concentration increased by quinine; avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval and phenothiazines; increased risk of arrhythmias with clozapine\n
  • Antivirals: concentration increased by ritonavir and possibly amprenavir increased risk of ventricular arrhythmias \u2013 avoid concomitant use\n
  • Diuretics: increased cardiac toxicity if hypokalaemia occurs5HT 3 antagonists: increased risk of ventricular arrhythmias with dolasetron \u2013 avoid concomitant use; use tropisetron with caution

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV bolus,

    IV infusion <\/H4>

    Rate of Administration <\/H4>See \u2018Other Information\u2019

    Comments<\/H4>Infusion: Dilute with 5% glucose infusion; if chloride containing solutions are used the injection should be added to a volume of not less than 500 mL, otherwise a precipitate will formPlasma levels of 200\u20131000 nanograms\/mL may be needed to obtain the maximum therapeutic effect. Plasma levels above Flecainide acetate.FLECAinidE ACETATE 309700\u20131000 nanograms\/mL are associated with increased likelihood of adverse events

    OTHER INFORMATION <\/H4>Product information recommendation: patients with severe renal impairment (defined as being a creatinine clearance <35 mL\/minute), reduce each dose recommended for

    IV infusion <\/H4> by halfProduct information recommendation: patients with severe renal impairment as defined above, that the maximum initial oral dosage should be 100 mg daily (or 50 mg twice daily) with frequent plasma level monitoring strongly recommendedElectrolyte disturbances should be corrected before using flecainidePlasma levels quoted in product information are trough levels. Sample prior to dose
    \n","protected":false},"excerpt":{"rendered":"

    Flecainide acetate CLINICAL USE Class Ic anti-arrhythmic agent:Ventricular arrhythmias and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3993","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3993"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3993\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}